CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.

When AstraZeneca announced plans to move from Alderley Park to Cambridge, U.K., in 2013, the new building was expected to cost £330 million. Now that has expanded to £1 billion (about $1.3 billion), three times the original estimate.

Adaptive Biotechnologies announced plans to lease a new corporate headquarters, tripling the company’s footprint in Seattle.

Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.

With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.

Cerecor Inc. announced that the company moved its U.S. corporate offices to Rockville, Maryland after previously being based in Baltimore.

London-based Autolus Therapeutics announced plans to locate the company’s U.S. headquarters in Rockville, Maryland.

Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.

Teva Pharmaceutical Industries Limited is moving its U.S. headquarters to Parsippany-Troy Hills, New Jersey, as part of a plan to centralize the company’s operations on the continent.

Ipsen plans to relocate the French company’s U.S. operations from New Jersey to Kendall Square in Cambridge, Mass.